---
title: "Black Hawk merger target Vesicor overhauls leadership team"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274698312.md"
description: "Black Hawk Acquisition Corporation announced leadership changes at its merger target, Vesicor Therapeutics, following the death of CFO Michael Bowen. Mitchell Creem has been appointed as the new CFO, while Frederick Woodruff Field joins as an independent director. These changes aim to stabilize Vesicor's governance as it moves forward with the merger, reassuring investors about financial oversight and board independence. Black Hawk, a SPAC, seeks to take Vesicor public and support its growth in the healthcare sector."
datetime: "2026-02-03T18:27:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274698312.md)
  - [en](https://longbridge.com/en/news/274698312.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274698312.md)
---

# Black Hawk merger target Vesicor overhauls leadership team

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Black Hawk Acquisition Corporation Class A ( (BKHA) ) has provided an announcement.

On January 27, 2026, Black Hawk Acquisition Corporation reported that Michael Bowen, the Chief Financial Officer of its proposed merger target Vesicor Therapeutics, Inc., had died, prompting Vesicor’s board to appoint veteran healthcare executive Mitchell Creem as its new CFO effective immediately, without an employment agreement. Separately, on January 26, 2026, Vesicor added experienced media and entertainment executive and investor Frederick Woodruff Field as an independent director, with both appointments expected to stabilize Vesicor’s leadership and governance structure as it pursues its planned business combination with Black Hawk, potentially reassuring investors and other stakeholders about continuity in financial oversight and board independence following the unexpected loss of its prior finance chief.

**More about Black Hawk Acquisition Corporation Class A**

Black Hawk Acquisition Corporation Class A is a special purpose acquisition company (SPAC) that has proposed a business combination with Vesicor Therapeutics, Inc., positioning it as a vehicle to take Vesicor public and provide capital for its growth. Vesicor operates in the therapeutics and healthcare sector, and the transaction would align Black Hawk’s market focus with innovative healthcare and life sciences opportunities.

**Average Trading Volume:** 3,110

**Technical Sentiment Signal:** Strong Buy

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BKHA.US](https://longbridge.com/en/quote/BKHA.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)